Metabolomic signatures for drug response phenotypes: Pharmacometabolomics enables precision medicine

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 1, 2015, Pages 71-75

  Kaddurah Daouk, R ^a   Weinshilboum, R ^b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARIPIPRAZOLE; ATENOLOL; BIOLOGICAL MARKER; CLOPIDOGREL; HYDROCHLOROTHIAZIDE; LITHIUM; OLANZAPINE; PRAVASTATIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; PHARMACOLOGICAL BIOMARKER;

ARTICLE; BIOENGINEERING; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; ENVIRONMENTAL EXPOSURE; HUMAN; METABOLOMICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHARMACOMETABOLOMICS; PHENOTYPE; PRIORITY JOURNAL; SCALE UP; SYSTEMS BIOLOGY; TREATMENT OUTCOME; DRUG DEVELOPMENT; METABOLISM; METABOLOME; PHARMACOGENETICS; PHARMACOLOGY;

BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; PHARMACOGENETICS; PHARMACOLOGY; PHENOTYPE;

EID: 84940545374     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.134     Document Type: Article

References (24)

1. Kaddurah-Daouk R, & Weinshilboum R.M. Pharmacometabolomics: implications for clinical pharmacology, and systems pharmacology. Clin. Pharmacol. Ther. 95(2), 154-167 (2014).
2. Patti G.J, Yanes O, & Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell. Biol. 13, 263-269 (2012).
3. Li H, & Jia W. Cometabolism of microbes, and host: implications for drug metabolism, and drug-induced toxicity. Clin Pharmacol Ther. 94(5), 574-581 (2013).
4. Kaddurah-Daouk R, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry. 1, pii: e26 (2011).
5. Zhu H, et al. Pharmacometabolomics Research Network. Pharmacometabolomics of response to sertraline, and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One 8(7), e68283 (2013).
6. Kaddurah-Daouk R, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline, and placebo. Transl. Psychiatry 3, e223 (2013).
7. Yerges-Armstrong L.M, et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomicsinformed pharmacogenomics. Clin. Pharmacol. Ther. 94(4), 525-532 (2013).
8. Yao J.K, et al. Associations between purine metabolites, and clinical symptoms in schizophrenia. PLoS One 7(8), e42165 (2012).
9. Abo R, et al. Merging pharmacometabolomics with pharmacogenomics using 1000 Genomes single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet. Genomics 22(4), 247-253 (2012).
10. Ji Y, et al. Glycine, and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 89(1), 97-104 (2011).
11. Perroud B, et al. Pharmacometabolomic signature of ataxia SCA1 mouse model, and lithium effects. PLoS One 8(8), e70610 (2013).
12. Fan T.W, et al. Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism, and interactions. Metabolomics 6(2), 165-179 (2010).
13. Krauss R, Zhu H, & Kaddurah-Daouk R. Pharmacometabolomics of statin response. Clin. Pharmacol. Ther. 94(5), 562-565 (2013).
14. Trupp M, et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS One 7(7), e38386 (2012).
15. Kaddurah-Daouk R, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One 6(10), e25482 (2011).
16. Kaddurah-Daouk R, et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol, and Pharmacogenetics Study. Metabolomics 6(2), 191-201 (2010).
17. Wikoff W.R, et al. Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One 8(3), e57639 (2013).
18. Cooper-Dehoff R.M, et al. Is diabetes mellitus-linked amino acid signature associated with b-blocker-induced impaired fasting glucose? Circ. Cardiovasc. Genet. 7(2), 199-205 (2014).
19. Ellero-Simatos S, et al. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst. Pharmacol. 3, e125 (2014).
20. Lewis J.P, Yerges-Armstrong L.M, Ellero-Simatos S, Georgiades A, Kaddurah-Daouk R, & Hankemeier T. Integration of pharmacometabolomic, and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin. Pharmacol. Ther. 94(5), 570-573 (2013).
21. McEvoy J, et al. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One 8(7), e68717 (2013).
22. Kaddurah-Daouk R, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12(10), 934-945 (2007).
23. Clayton T.A, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440(7087), 1073-1077 (2006).
24. Haiser H.J, et al. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 5(2), 233-238 (2014).